News & Videos - VERITAS PHARMA INC VRTHF - Page 2

VANCOUVER, B.C., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce along with the Institute for Medical Cannabis (the “IMC” ) of Puerto Rico, the signing of a Memorandum of Understanding ( “MOU” ) between the two entities for the investigation and commercialization of new pharmaceutical products within the Commonwealth of Puerto Rico. The MOU represents the first of its kind...

VANCOUVER, British Columbia, Sept. 30, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding ( “MOU” ) with Agrima Botanicals Corp ( “Agrima” ) where both companies will share the intellectual property ( “IP” ) jointly developed as part of a proposed agreement that outlines a medical cannabis research collaboration. Under the terms of...

VANCOUVER, British Columbia, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to provide a corporate update on its activities, milestones over the first three quarters of 2018, and strategies for growth in the new year. Launch of Cannevert’s Testing Services for Revenue and the Lease of New Research Facility Veritas’ subsidiary, Cannevert Therapeutics Ltd. ( “CTL” ) is preparing to offer...

VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that 3 Carbon Extractions Inc. ( “3 CARBON” ), an industry leader in regulatory compliant cannabis hydrocarbon extraction solutions, has entered into a Memorandum of Understanding ( “MOU” ) with Rubikon Blockchain Corporation ( “Rubikon” ) to establish secure infrastructure for the tracking of...

VANCOUVER, British Columbia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that its subsidiary, 3 Carbon Extractions Inc. ( “3 CARBON” ), has completed an exclusive marketing rights relationship with ExtractionTek Solutions Inc. ( “ETS” ) located in Denver, Colorado, U.S. ETS is a recognized international leader in closed loop hydrocarbon extraction equipment. Their lines of...

VANCOUVER, British Columbia, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce the appointment of Lorne Mark Roseborough as a Director of the Company. Lui Franciosi commented: “We are very pleased to welcome Mr. Roseborough to Veritas’ Board of Directors. He has knowledge of our growing industry and his experience in equity markets will be a significant asset to us as we continue to...

VANCOUVER, British Columbia, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that the Company has completed the Share Purchase Agreement ( “Purchase Agreement” ) to acquire Fifty Percent (50%) of the issued and outstanding shares of 3 Carbon Extractions Inc. ( “3 CARBON” ). Under the terms of the Agreement as previously announced on April 16, 2018 , Veritas has invested...

VANCOUVER, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that it has signed a Memorandum of Understanding ( “MOU” ) with IsCann Group Limited ( “IsCann” ) located in Be'er Tuvya, Israel with the aim of establishing, maintaining, and expanding business in the Canadian and Israeli medical cannabis sector. Under the terms of the MOU, both parties will identify...

VANCOUVER, British Columbia, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company) is pleased to announce that it has entered into a Memorandum of Understanding ( “MOU” ) with the Chamber of Commerce, Industry, Services and Tourism Brazil & Puerto Rico ( “C2BPR” ) with the aim of helping to commence, maintain, and expand businesses in the medical cannabis sector for the Brazil and Puerto Rico markets. Under...

VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June 25, 2018 that it would stop dealing with all North American cannabis stocks, has revised its decision to now solely deal with companies focused on medical cannabis such as Veritas. To read the...

VANCOUVER, British Columbia, July 17, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce that it has signed an Intellectual Property Sharing Agreement ( “Joint IP” ) with Sativa Investments PLC ( “Sativa” ) (NEX:SATI), UK’s first medicinal cannabis investment fund. Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead...

VANCOUVER, British Columbia, June 25, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that Mr. Filios Theodorou has been appointed as its business development agent in Cyprus. He will report to CEO, Dr. Lui Franciosi and undertake the Company’s business interests in medical cannabis industry not only in Cyprus but also in other parts of Southern Europe, Middle East and Africa ( “SEM E A” )....

VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP) , (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding ( “MOU” ) with Colombian medical cannabis company Foliumed S.A.S. ( “Foliumed” ). Under the terms of the MOU, Veritas and Foliumed will jointly conduct scientific research, undertake product development activities, and commercialize select medical...

VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) , (“Veritas” or the “Company”) is pleased to provide a corporate update on its achievements, related scientific activities and growth strategies for the second quarter of fiscal 2018. Status of Human Trials Earlier this year, Veritas Pharma’s subsidiary Cannevert Therapeutics ( “CTL” ) signed an agreement with Puerto Rico’s Fundación de Investigación (...

VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) , (“Veritas” or the “Company”) is pleased to announce with the dealer licence being granted which was previously announced on December 28, 2017 , the Company has now engaged a branding firm in the development of label and package design in compliance of Health Canada regulations. Veritas is applying to amend Cannevert’s Dealer Licence such that the Company can package...

VANCOUVER, British Columbia, May 10, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) provides the following statement to the recommendation issued by Members of the Standing Senate Committee on Aboriginal Peoples calling for a one-year deferment to allow for further consultation with Indigenous groups on May 1, 2018. Members of the of the Standing Senate Committee on Aboriginal Peoples in the Canadian Senate are...

VANCOUVER, British Columbia, May 07, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce the establishment of new subsidiary Veritas Pharma Puerto Rico LLC ( “Veritas PR” ) in the US territory. With the management and regulatory guidance of Essèntium Group LLC, Veritas PR establishes a foothold for the scientific investigation, product development and commercialization of cannabis-based therapies in...

VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) , (“Veritas” or the “Company”) is pleased to announce that Dr. Michael K. Pugsley PhD, FBPhS, DSP, a consultant in safety pharmacology, has joined its advisory board. Dr. Pugsley is a safety pharmacologist and toxicologist specialized in a variety of therapeutic areas in drug development, in particular, central nervous system, anti-inflammatory, oncology, myocardial...

3 Carbon is in the business of designing cannabis extraction facilities and utilizing its own proprietary extraction methods. VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Share Purchase Agreement ( “ Purchase Agreement” ) with 3 Carbon Extractions Inc. ( “3 Carbon” ) to acquire Fifty Percent (50%) of the issued and outstanding...

CALGARY, Alberta, Feb. 28, 2018 (GLOBE NEWSWIRE) -- BioCan Technologies Inc. (“ BioCan ” or the “ Company ”) is pleased to announce that it has entered into a Memorandum of Understanding (“ MoU ”) with Veritas Pharma Inc. (“ Veritas ”) (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) to collaborate with Veritas on an exclusive basis to undertake further investigations of cannabis strains being developed by the research arm of Veritas, Cannevert Therapeutics Ltd. (“ CTL ”). The focus...